DynaPro™ Plate Reader Dynamic and Static Light Scattering Detector
Automated characterization of protein/nanoparticle size, stability and molecular weight in industry-standard microwell plates
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Pleasure to work on the instrument and interact with Wyatt's specialists.
Structural biology
Fast measurement for sample evaluation in many different conditions and concentrations.
Review Date: 25 Jul 2024 | Waters
The DynaPro™ Plate Reader performs automated analysis of the size and molar mass of peptides, proteins, polymers, nanoparticles and emulsions using dynamic and static light scattering (DLS and SLS) in microwell plates.
All measurements take place in situ in microwell plates with no additional liquid handling, and samples are fully recoverable. The DynaPro™ enables novel, high-throughput workflows that simply would not be possible with typical cuvette-based DLS instruments.
Features:
- Uses industry-standard, flat-bottom 96, 384 or 1536-well plates
- DLS Sensitivity: 0.125 µg of 14.4 kDa lysozyme
- Hydrodynamic radius (Rh) range: 0.5 – 1000 nm
- SLS sensitivity: 1 mg/mL of 66.7 kDa BSA
- Molar mass range: 1 kDa – 1 MDa
- Minimum sample volume: 4 µL in 1536-well plates
- Temperature control: 4 – 85 °C
- Typical scan time for a fully-loaded 386-well plate: 90-120 minutes
- Infrared laser wavelength of 830 nm, not susceptible to fluorescence
- Embedded camera images the bottom of each well to identify precipitation, turbidity and bubbles
- Touch-panel display for immediate access to data, diagnostics and settings
- Software: DYNAMICS™ analysis software offers easy Experiment Builder method setup; comprehensive analysis of size and size distributions, molar mass, diffusion interaction parameter kD, second virial coefficient A2, thermal behavior Tagg/Tm/Tonset, DLS-based viscosity; versatile heatmap display of results; full export of all results; optional 21CFR11 support for GMP
Applications:
- Screen biotherapeutic candidates and formulations for developability and stability.
- Protein quality control before interaction screening
- Optimize protein buffers for crystallization and purification
- Identify ideal dissolution and processing conditions for nanoparticle or polysaccharide production
- Critical micelle concentration and temperature of surfactants or polymers
Automated dynamic and static light scattering in microwell plates for fast, productive development of biologics
High-throughput screening of biologics demands precise, efficient measurement of size and stability, yet traditional methods can be slow and complex. Researchers need tools that simplify analysis without compromising data quality.
Discover how dynamic light scattering technology supports robust, simultaneous measurement of key biophysical properties across proteins, nanoparticles, and therapeutic candidates.
Particle size analysis by DLS for optimization of protein complexes for measurement by small-angle neutron scattering
Explore how dynamic light scattering (DLS) can be used to ensure monodispersity in protein samples for small-angle neutron scattering (SANS) studies. Discover how researchers using the DynaPro™ Plate Reader, detected protein aggregation that was undetectable by SDS-PAGE and UV spectroscopy. This method enhances sample quality assessment, ensuring reliable SANS measurements for studying Type I bacterial restriction-modification systems.
Characterization of AAV-based viral vectors by DynaPro DLS/SLS instruments
In this application note, Wyatt Technology explores the utilization of the DynaPro Plate Reader and DynaPro NanoStar instruments for the quantification of three quality attributes (QAs) of AAV drug products: aggregate content, thermal stability, and total viral particle concentration. These two technologies, which combine dynamic light scattering (DLS) and static light scattering (SLS) respectively, represent low-volume, quick-screening tools for quantifying AAV quality attributes.
Quantifying quality attributes of AAV gene therapy vectors by SEC-UV-MALS-dRI
In this application note, Wyatt Technology present a simple and direct size-exclusion chromatography method with UV-MALS-dRI detection, which can be readily employed to quantify AAV particle concentration, capsid content, and aggregation throughout the AAV product development and manufacturing processes.
Real-time product attributes, from lab to plant
Process analytical technologies are a key enabler of quality by design (QbD) and Bioprocess 4.0. Implementation of light-scattering based process analytical technology (PAT), inline and online, shifts the focus of PAT from process parameters to product parameters and hints at a pathway to real-time release. Learn more about multi-angle light scattering as an analytical technology for biopharmaceuticals and nanomedicines, and explore the methods available for utilizing real-time MALS as a PAT tool from process development to scale-up and production.
Leveraging light scattering techniques for enhanced biotherapeutic characterization and development
Prof. Dr. Hristo L. Svilenov, Professor of Biopharmaceutical Technology at Ghent University, and Dr. Lorenzo Gentiluomo, Senior Sales Account Manager at Waters/Wyatt Technology, will present several case studies demonstrating the use of various light scattering techniques for the advanced characterization of biopharmaceutical samples. They will focus on dynamic light scattering (DLS), size-exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) and real-time multi-angle light scattering (RT-MALS).
Key learning objectives
- Learn the basics of light scattering techniques
- Discover how to effectively distinguish between different light scattering methods, including DLS, SLS, SEC-MALS and RT-MALS
- Understand how different light scattering can be used to characterize therapeutic proteins
Who should attend?
Scientists interested in the analytical characterization of biopharmaceuticals using light scattering techniques.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Advancing light scattering assays for AAV products
March 19, 15:00 GMT/ 16:00 CET/ 11:00 EDT/ 08:00 PDT
AAV-based gene therapy products are heterogeneous, composed of empty, partial, and full monomer capsid species as well as capsid aggregates and fragments. Join our exclusive webinar where Dr Margaret Butko, Director of CMC Assay Development, Adverum and Dr. Prithwijit Sarkar, Sr. System Account Manager, Waters|Wyatt Technology, will present two methods: GMP-compliant DLS (dynamic light scattering) which is used for monitoring capsid aggregation, including generation of a capsid aggregation standard, and the FFF-MALS (field-flow fractionation coupled with multi-angle light scattering) method, used for quantifying the relative abundance of capsid aggregates.
Explore these two methods, with the addition of quantification platform SEC-MALS (size exclusion chromatography coupled with multi-angle light scattering), to quantify the relative abundance of both capsid aggregates and full capsids. Find out how you can elevate your AAV-based gene therapy research with these tools and ensure the delivery of consistent products to patients.
Key learning objectives:
- Explore DLS applications to monitor capsid aggregation in a GMP setting
- Discover FFF-MALS applications to quantify the relative abundance of capsid aggregates
- Investigate SEC-MALS applications to quantify the relative abundance of full capsids
Who should attend?
- CMC teams supporting AAV-based therapies
- Scientists involved in AAV characterization, analytical method development, process development, and quality control
- Lab managers that need to select and support an optimal set of AAV characterization methods
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Experimental methodology in a core facility: Light scattering for preliminary experiments and final answers
As a core analytical facility, we are approached by users seeking our services with a large variety of samples. They usually have specific experiments/equipment in mind, frequently desiring to use the most intensive experimental techniques (in terms of sample, time, and money), when a simpler technique could give them the answers they require at a fraction of the cost. Often our recommended techniques include preliminary analysis with dynamic light scattering (DLS), followed by multi-angle light scattering (MALS), instead of analytical ultracentrifugation (AUC) or other high-maintenance biophysical techniques.
In this webinar expert speakers will explain, with a few examples, the methodology we have developed to save users time, sample, and money by prioritizing certain techniques for preliminary experiments. Many times the results from these ‘preliminary’ experiments are sufficient to provide the answers to the questions our researchers are asking.
Key learning objectives
- The fundamentals of light scattering theory, instrumentation and applications
- How light scattering instruments are used for fast, preliminary experiments before more intensive studies are attempted
- How often preliminary experiments provide all the answers needed for the scientific question
- Advantages (and some disadvantages) of Wyatt’s DLS and MALS instruments in relation to other techniques such as AUC.
Who should attend?
- Customers of biophysical core facilities or CROs who are considering light scattering in relation to other techniques
- Lab managers responsible for biophysical characterization who would like to optimize facility workflows, productivity, and use
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
The biopharma innovations transforming patient health
Explore innovations such as oligonucleotide therapeutics, bi-specific antibodies, CAR-T therapy and CRISPR
